about
Germline mutations in BAP1 predispose to melanocytic tumorsTERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.CD10 immunohistochemical staining in urothelial neoplasmsPhylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination.BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma.MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.Kinase fusions are frequent in Spitz tumours and spitzoid melanomas.Squamous precursor lesions of the vulva: current classification and diagnostic challenges.Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.Copy number alteration burden predicts prostate cancer relapseDNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterationsA recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.MAGI-2 scaffold protein is critical for kidney barrier function.Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.Dabrafenib and its potential for the treatment of metastatic melanoma.Assessment of SLX4 Mutations in Hereditary Breast Cancers.The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients.TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma.Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas.A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression.Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathwayGNAQ and GNA11 mutations in melanocytomas of the central nervous systemClear cell atypical fibroxanthoma - report of a case with review of the literature.Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathwayEndocrine mucin-producing sweat gland carcinoma: report of a case and review of the literature.Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.Alternative transcription initiation leads to expression of a novel ALK isoform in cancer.Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapyTERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours.Secondary Involvement of the Adnexa and Uterine Corpus by Carcinomas of the Uterine Cervix: A Detailed Morphologic DescriptionTFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis.Perivascular epithelioid tumours (PEComas) of the gynaecological tractMorphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.The detection and significance of melanoma micrometastases in sentinel nodes.Development of a risk stratification system to guide treatment for female germ cell tumors.Sentinel lymph node biopsy for melanoma: aspects of pathologic assessment.Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors.Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier.Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis.Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma.
P50
Q24594891-FD7A97AA-0A53-41E9-8F0F-1710B6D7A2B5Q27853068-C3A7DEF3-1A2C-4F65-B9EA-3FF0437206D1Q28274521-A83C230F-A08B-4426-9EEB-AEB7BE721B39Q30403025-BDB1578C-84AA-4843-8992-E55DB8F03B82Q30457154-A0C84DB0-1083-49B6-AD46-B16E9C186DF5Q33694015-B6547DA0-75DA-47C3-94A9-032A8FCC0BD6Q33854847-F970F9E5-8998-4830-8B75-0D9C2E522D9FQ33920308-0B4611BD-F433-44C7-B66B-2405868C7D57Q33923045-DEED79A0-AA2C-4CC5-BB27-C33D7759DD7CQ34002312-48FA7ADA-A312-4E6E-8F56-277E787D1262Q34359695-89967A62-4100-4B36-8C84-D388B2F2C7CFQ34369388-5CD252D9-491C-48DD-9A88-35C5F9A2359EQ34384101-A7E254ED-6F9B-4499-AED6-B868F0513DC5Q34390313-2BA7D7CB-6C14-4409-BEAD-537A8DE1FA41Q34646614-CCDBF034-203E-47EC-93B6-341CC2189FEDQ34806183-2DFCF669-1766-4F06-ABD1-7031AF8AD44CQ35001487-C36A7D96-538D-4435-9931-F6471828AB48Q35048963-29D98BC8-6557-4074-A72E-C2DFBC421DE9Q35783825-3BFC7AA4-329C-4FC8-81E0-A1D86F261268Q35965678-0ACCF634-F610-4824-B6BE-8FB89F08ACB2Q36109039-D5FAA6A1-1C8D-4F6F-8C7A-F0F86360082CQ36391571-C837E248-C7AD-44B7-96B7-C58E28164D91Q36460880-C65B48F1-AE3E-48C4-BC07-EB218DA50CA3Q36546559-10FAC054-3204-4582-A30D-E7F6631F3EB4Q36687509-7C703AA1-824D-48C3-85E4-FB99FE23DF56Q36689039-74E25C84-020C-4137-B70F-8CD0A0333A32Q36726792-B192E0ED-1BF7-402A-9ACF-C4D75C5895AEQ36755569-6B7E249A-0EE8-4954-9E1A-14E19E8EB8D1Q37040678-D1E4DEF9-E370-4DF6-B2E5-1B50A158A150Q37158176-A5CFD30E-396B-4A0A-9803-18A629EA35E0Q37170478-FBE9F38C-5BF0-41B8-98FB-00F760254CEBQ37173539-D8A5699E-613A-4281-821C-EEF08F44F872Q37196721-9ECCA193-6833-430D-8B66-6C043D27BAFBQ37221175-68854167-970E-4841-A9B9-5478BAC1E2B4Q37234753-70ECF28C-8C96-4CAF-9EAF-B785AA280B0FQ37236435-646952A9-2486-44BC-81AC-8905232B535BQ37296614-9C7297F4-2D1C-4769-BADC-20A8A318F404Q37356519-2C3609FE-9071-4772-90EF-FC632BAC4E57Q37380194-30F7915D-6A45-423E-9C92-40DE2999A597Q37399871-05A908E4-3517-487E-BA0C-2AB584B1F428
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rajmohan Murali
@ast
Rajmohan Murali
@en
Rajmohan Murali
@es
Rajmohan Murali
@nl
Rajmohan Murali
@sl
type
label
Rajmohan Murali
@ast
Rajmohan Murali
@en
Rajmohan Murali
@es
Rajmohan Murali
@nl
Rajmohan Murali
@sl
prefLabel
Rajmohan Murali
@ast
Rajmohan Murali
@en
Rajmohan Murali
@es
Rajmohan Murali
@nl
Rajmohan Murali
@sl
P1053
A-7960-2008
P106
P1153
22953995200
P31
P3829
P496
0000-0001-6988-4295
P569
2000-01-01T00:00:00Z